AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Elite Pharmaceuticals, Inc.
Video analysis: ELTP
All videosNo video analysis for this stock yet. Request one from our team.
News: ELTP
ELTP Downgraded to Neutral on Pricing Pressure & Limited Visibility
Elite Pharmaceuticals' downgrade to Neutral cites pricing pressure, weaker revenue and margins, and limited visibility into new-product contributions.
ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?
Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.
Elite Pharmaceuticals Stock Plunges Post Q1 Earnings, Revenues Fall Y/Y
ELTP's first-quarter fiscal 2027 revenues decline as generic competition and lower pricing offset higher volumes, while pipeline development remains a growth focus.
Elite Pharmaceuticals, Inc. (ELTP) Q1 2027 Earnings Call Transcript
Elite Pharmaceuticals, Inc. (ELTP) Q1 2027 Earnings Call Transcript
Elite Pharmaceuticals Q1 Earnings Call Highlights
Elite Pharmaceuticals OTCMKTS: ELTP reported first-quarter fiscal 2027 revenue of $32.4 million and operating profit of $7.5 million, with Chief Financial Officer Carter Ward describing both measures as steady and consistent with the preceding three quarters.
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information
Conference Call Scheduled for Friday, August 14, 2026 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - August 13, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2027 ended June 30, 2026 ("First Quarter"). Consolidated revenues for the three-month period ending June 30, 2026, were $32.4 million, a decrease of $7.9 million or approximately 19.5% as compared to the same period of the prior fiscal year in which Elite had the largest quarterly revenue in its history.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter of Fiscal Year 2027 Financial Results on August 14, 2026
Financials for First Quarter of Fiscal Year 2027 Ended June 30, 2026 will be released on Thursday, August 13, 2026 Northvale, New Jersey--(Newsfile Corp. - August 10, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2027 fiscal year will be released on Thursday, August 13, 2026. Elite's management will host a live conference call on Friday, August 14th, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update.
Elite Pharmaceuticals Announces Commercial Launch of Generic Requip XL
Northvale, New Jersey--(Newsfile Corp. - August 4, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Requip XL® (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets. Ropinirole belongs to a class of drugs known as a non-ergoline dopamine agonist used to treat Parkinson's disease.
